INITIAL REPORT OF PART B PHASE 1/2 EFFICACY AND SAFETY RESULTS FOR BRUTON TYROSINE KINASE INHIBITOR RILZABRUTINIB IN PATIENTS WITH RELAPSED IMMUNE THROMBOCYTOPENIA

被引：0
|
作者：
Cooper, Nichola [1 ]
Jansen, A. J. Gerard [2 ]
Mayer, Jiri [3 ]
Tarantino, Michael D. [4 ]
Diab, Remco [5 ]
Ward, Brad [6 ]
Daak, Ahmed [6 ]
Kuter, David J. [7 ]
机构：
[1] Hammersmith Hosp, London, England
[2] Univ Med Ctr, Erasmus MC, Rotterdam, Netherlands
[3] Masaryk Univ Hosp, Brno, Czech Republic
[4] Univ Illinois, Bleeding & Clotting Disorders Inst, Coll Med Peoria, Peoria, IL USA
[5] Sanofi, Rotkreuz LU, Vernier, Switzerland
[6] Sanofi, Cambridge, MA USA
[7] Harvard Med Sch, Massachusetts Gen Hosp, Div Hematol, Boston, MA 02115 USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2024年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：29 / 29
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study
    Cooper, Nichola
    Jansen, A. J. Gerard
    Bird, Robert
    Mayer, Jiri
    Sholzberg, Michelle
    Tarantino, Michael D.
    Garg, Mamta
    Ypma, Paula F.
    Mcdonald, Vickie
    Percy, Charles
    Kostal, Milan
    Goncalves, Isaac
    Bogdanov, Lachezar H.
    Gernsheimer, Terry B.
    Diab, Remco
    Yao, Mengjie
    Daak, Ahmed
    Kuter, David J.
    AMERICAN JOURNAL OF HEMATOLOGY, 2025, 100 (03) : 439 - 449
  • [2] Disorders of Platelet Number or Function: Clinical and Epidemiological Initial Report of Part B Phase 1/2 Efficacy and Safety Results for Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed Immune Thrombocytopenia
    Cooper, Nichola
    Jansen, A. J. Gerard
    Bird, Robert
    Mayer, Jiri
    Sholzberg, Michelle
    Tarantino, Michael D.
    Garg, Mamta
    Ypma, Paula F.
    McDonald, Vickie
    Percy, Charles
    Kostal, Milan
    Goncalves, Isaac
    Bogdanov, Lachezar H.
    Gernsheimer, Terry B.
    Diab, Remco
    Yao, Mengjie
    Daak, Ahmed
    Kuter, David J.
    BLOOD, 2023, 142
  • [3] Updated Phase I/II Safety and Efficacy Results for Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed/Refractory Immune Thrombocytopenia
    Kuter, David J.
    Tzvetkov, Nikolay
    Efraim, Merlin
    Kaplan, Zane
    Mayer, Jiri
    Choi, Philip
    Jansen, A. J. Gerard
    McDonald, Vickie
    Baker, Ross
    Bird, Robert J.
    Garg, Mamta
    Gumulec, Jaromir
    Kostal, Milan
    Gernsheimer, Terry
    Ghanima, Waleed
    Bandman, Olga
    Arora, Puneet
    Burns, Regan
    Yao, Mengjie
    Daak, Ahmed
    Sourdille, Timothee
    Iqbal, Fareha
    Thomas, Dolca
    Neale, Ann
    Cooper, Nichola
    BLOOD, 2021, 138
  • [4] LONG-TERM EFFICACY AND SAFETY WITH ORAL BRUTON TYROSINE KINASE INHIBITOR RILZABRUTINIB IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA
    Kuter, David J.
    Gernsheimer, Terry
    Ghanima, Waleed
    Khan, Umer
    Ward, Brad
    Daak, Ahmed
    Cooper, Nichola
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 100 : 71 - 71
  • [5] Part a Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Patients with Warm Autoimmune Hemolytic Anemia (wAIHA): Multicenter, Open-Label, Phase 2b Study
    Cooper, Nichola
    Kuter, David J.
    Frederiksen, Henrik
    Han, Bing
    Chen, Frederick
    Barcellini, Wilma
    Cid, Joan
    Broome, Catherine M.
    Vara, Miriam
    Mazumder, Amitabha
    Lucchesi, Alessandro
    Zhao, Xin
    Risitano, Antonio M.
    Sawhney, Sumit
    Hill, Quentin A.
    Jayawardene, Deepthi
    Diab, Remco
    Zhao, Jing
    Daak, Ahmed
    BLOOD, 2024, 144 : 3836 - 3837
  • [6] Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study
    Jones, Jeffrey
    Andritsos, Leslie
    Kreitman, Robert J.
    Ravandi, Farhad
    Schiffer, Charles
    Call, Timothy G.
    Lozanski, Gerard
    Harris, Pamela
    Sexton, Jennifer
    Ruppert, Amy S.
    Grever, Michael R.
    BLOOD, 2016, 128 (22)
  • [7] SAFETY AND EFFICACY OF THE BRUTON TYROSINE KINASE INHIBITOR IBRUTINIB IN PATIENTS WITH HAIRY CELL LEUKEMIA: INTERIM RESULTS OF A PHASE 2 STUDY
    Jones, J. A.
    Andritsos, L.
    Ravandi, F.
    Kreitman, R. J.
    Schiffer, C.
    Call, T.
    Lozanski, G.
    Sexton, J.
    Harris, P.
    Grever, M. R.
    HAEMATOLOGICA, 2015, 100 : 313 - 313
  • [8] Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study
    Chari, Ajai
    Chhabra, Saurabh
    Usmani, Saad
    Larson, Sarah
    Niesvizky, Ruben
    Matous, Jeffrey
    Gasparetto, Cristina
    Holkova, Beata
    Lunning, Matthew
    Valent, Jason
    Anderson, Larry D., Jr.
    Karanes, Chatchada
    Kwei, Long
    Chang, Lipo
    Graef, Thorsten
    Bilotti, Elizabeth
    McDonagh, Kevin
    BLOOD, 2015, 126 (23)
  • [9] Efficacy and Safety of Tyrosine Kinase Inhibitors in the Treatment of Relapsed/Refractory Immune Thrombocytopenia
    Ali, Muhammad Ashar
    Saeed, Memoona
    Supraja, A.
    Zafar, Maha
    Nepal, Ashish
    Suleman, Muhammad
    Habib, Rooma
    Rashid, Sana
    Asfund, Sumaiya
    Basit, Muhammad Abdul
    Zahoor, Hafsa
    Kosach, Sviatoslav
    Anwar, Aqsa
    Aiman, Wajeeha
    BLOOD, 2022, 140 : 8408 - 8409
  • [10] Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease
    Langrish, Claire L.
    Bradshaw, J. Michael
    Francesco, Michelle R.
    Owens, Timothy D.
    Xing, Yan
    Shu, Jin
    LaStant, Jacob
    Bisconte, Angelina
    Outerbridge, Catherine
    White, Stephen D.
    Hill, Ronald J.
    Brameld, Ken A.
    Goldstein, David M.
    Nunn, Philip A.
    JOURNAL OF IMMUNOLOGY, 2021, 206 (07): : 1454 - 1468
12345